Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Heart Failure Reviews
Erschienen in: Heart Failure Reviews 1/2017

17.11.2016

Metabolic enzymes dysregulation in heart failure: the prospective therapy

verfasst von: Priyanka Parihar, Mordhwaj Singh Parihar

Erschienen in: Heart Failure Reviews | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

The heart failure accounts for the highest mortality rate all over the world. The development of preventive therapeutic approaches is still in their infancy. Owing to the extremely high energy demand of the heart, the bioenergetics pathways need to respond efficiently based on substrate availability. The metabolic regulation of such heart bioenergetics is mediated by various rate limiting enzymes involved in energy metabolism. Although all the pertinent mechanisms are not clearly understood, the progressive decline in the activity of metabolic enzymes leading to diminished ATP production is known to cause progression of the heart failure. Therefore, metabolic therapy that can maintain the appropriate activities of metabolic enzymes can be a promising approach for the prevention and treatment of the heart failure. The flavonoids that constitute various human dietary ingredients also effectively offer a variety of health benefits. The flavonoids target a variety of metabolic enzymes and facilitate effective management of the equilibrium between production and utilization of energy in the heart. This review discusses the broad impact of metabolic enzymes in the heart functions and explains how the dysregulated enzyme activity causes the heart failure. In addition, the prospects of targeting dysregulated metabolic enzymes by developing flavonoid-based metabolic approaches are discussed.
Literatur
1.
Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J, Hoppel CL (2001) Mitochondrial dysfunction in cardiac disease: ischemia—reperfusion, aging, and heart failure. J Mol Cell Cardiol 33:1065–1089PubMedCrossRef
2.
3.
Sliwa K, Damasceno A, Mayosi BM (2005) Epidemiology and etiology of cardiomyopathy in Africa. Circulation 112:3577–3583PubMedCrossRef
4.
Ingwall JS, Weiss RG (2004) Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 95:135–145PubMedCrossRef
5.
Neubauer S (2007) Cardiac physiology investigated by new methods of imaging. Clin Med (Lond) 7:189–191CrossRef
6.
7.
Blache D, Devaux S, Joubert O, Loreau N, Schneider M, Durand P, Prost M, Gaume V, Adrian M, Laurant P, Berthelot A (2006) Long-term moderate magnesium-deficient diet shows relationships between blood pressure, inflammation and oxidant stress defense in aging rats. Free Radic Biol Med 41:277–284PubMedCrossRef
8.
Cantu D, Schaack J, Patel M (2009) Oxidative inactivation of mitochondrial aconitase results in iron and H2O2-mediated neurotoxicity in rat primary mesencephalic cultures. PLoS One 4:e7095PubMedPubMedCentralCrossRef
9.
Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, Korner R, Greff Z, Keri G, Stemmann O, Mann M (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31:438–448PubMedCrossRef
10.
Vahid F, Zand H, Nosrat-Mirshekarlou E, Najafi R, Hekmatdoost A (2015) The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review. Gene 562:8–15PubMedCrossRef
11.
Maron DJ (2004) Flavonoids for reduction of atherosclerotic risk. Curr Atheroscler Rep 6:73–78PubMedCrossRef
12.
Huxley RR, Neil HA (2003) The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur J Clin Nutr 57:904–908PubMedCrossRef
13.
Geleijnse JM, Launer LJ, Van der Kuip DA, Hofman A, Witteman JC (2002) Inverse association of tea and flavonoid intakes with incident myocardial infarction: the Rotterdam Study. Am J Clin Nutr 75:880–886PubMed
14.
15.
Zern TL, Fernandez ML (2005) Cardioprotective effects of dietary polyphenols. J Nutr 135:2291–2294PubMed
16.
Jeong YJ, Choi YJ, Kwon HM, Kang SW, Park HS, Lee M, Kang YH (2005) Differential inhibition of oxidized LDL-induced apoptosis in human endothelial cells treated with different flavonoids. Br J Nutr 93:581–591PubMedCrossRef
17.
Fuhrman B, Volkova N, Coleman R, Aviram M (2005) Grape powder polyphenols attenuate atherosclerosis development in apolipoprotein E deficient (E0) mice and reduce macrophage atherogenicity. J Nutr 135:722–728PubMed
18.
Hubbard GP, Wolffram S, de Vos R, Bovy A, Gibbins JM, Lovegrove JA (2006) Ingestion of onion soup high in quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in man: a pilot study. Br J Nutr 96:482–488PubMed
19.
Ludwig A, Lorenz M, Grimbo N, Steinle F, Meiners S, Bartsch C, Stangl K, Baumann G, Stangl V (2004) The tea flavonoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells. Biochem Biophys Res Commun 316:659–665PubMedCrossRef
20.
Hallund J, Bugel S, Tholstrup T, Ferrari M, Talbot D, Hall WL, Reimann M, Williams CM, Wiinberg N (2006) Soya isoflavone-enriched cereal bars affect markers of endothelial function in postmenopausal women. Br J Nutr 95:1120–1126PubMedCrossRef
21.
Hodgson JM (2006) Effects of tea and tea flavonoids on endothelial function and blood pressure: a brief review. Clin Exp Pharmacol Physiol 33:838–841PubMedCrossRef
22.
Mao TK, van de Water J, Keen CL, Schmitz HH, Gershwin ME (2002) Modulation of TNF-alpha secretion in peripheral blood mononuclear cells by cocoa flavanols and procyanidins. Dev Immunol 9:135–141PubMedPubMedCentralCrossRef
23.
Rein D, Paglieroni TG, Pearson DA, Wun T, Schmitz HH, Gosselin R, Keen CL (2000) Cocoa and wine polyphenols modulate platelet activation and function. J Nutr 130:2120S–2126SPubMed
24.
Stein JH, Keevil JG, Wiebe DA, Aeschlimann S, Folts JD (1999) Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation 100:1050–1055PubMedCrossRef
25.
26.
Sanbe A, Tanonaka K, Hanaoka Y, Katoh T, Takeo S (1993) Regional energy metabolism of failing hearts following myocardial infarction. J Mol Cell Cardiol 25:995–1013PubMedCrossRef
27.
28.
Erecinska M, Wilson DF (1982) Regulation of cellular energy metabolism. J Membr Biol 70:1–14PubMedCrossRef
29.
Leverve XM (2007) Mitochondrial function and substrate availability. Crit Care Med 35:S454–S460PubMedCrossRef
30.
Finck BN (2007) The PPAR regulatory system in cardiac physiology and disease. Cardiovasc Res 73:269–277PubMedCrossRef
31.
Rosca MG, Hoppel CL (2013) Mitochondrial dysfunction in heart failure. Heart Fail Rev 18:607–622PubMedCrossRef
32.
Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90:207–258PubMedCrossRef
33.
Beer M, Seyfarth T, Sandstede J, Landschutz W, Lipke C, Kostler H, von Kienlin M, Harre K, Hahn D, Neubauer S (2002) Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 40:1267–1274PubMedCrossRef
34.
Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK (1991) Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 338:973–976PubMedCrossRef
35.
Nascimben L, Friedrich J, Liao R, Pauletto P, Pessina AC, Ingwall JS (1995) Enalapril treatment increases cardiac performance and energy reserve via the creatine kinase reaction in myocardium of Syrian myopathic hamsters with advanced heart failure. Circulation 91:1824–1833PubMedCrossRef
36.
Tian R, Nascimben L, Kaddurah-Daouk R, Ingwall JS (1996) Depletion of energy reserve via the creatine kinase reaction during the evolution of heart failure in cardiomyopathic hamsters. J Mol Cell Cardiol 28:755–765PubMedCrossRef
37.
Kato T, Niizuma S, Inuzuka Y, Kawashima T, Okuda J, Tamaki Y, Iwanaga Y, Narazaki M, Matsuda T, Soga T, Kita T, Kimura T, Shioi T (2010) Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 3:420–430PubMedCrossRef
38.
Lei B, Lionetti V, Young ME, Chandler MP, d’Agostino C, Kang E, Altarejos M, Matsuo K, Hintze TH, Stanley WC, Recchia FA (2004) Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol 36:567–576PubMedCrossRef
39.
Duncan JG, Finck BN (2008) The PPARalpha-PGC-1alpha axis controls cardiac energy metabolism in healthy and diseased myocardium. PPAR Res 2008:253817PubMedCrossRef
40.
Wang S, Fu C, Wang H, Shi Y, Xu X, Chen J, Song X, Sun K, Wang J, Fan X, Wang H, Yang X, Huan T, Hui R (2007) Polymorphisms of the peroxisome proliferator-activated receptor-gamma coactivator-1alpha gene are associated with hypertrophic cardiomyopathy and not with hypertension hypertrophy. Clin Chem Lab Med 45:962–967PubMed
41.
Dai DF, Johnson SC, Villarin JJ, Chin MT, Nieves-Cintron M, Chen T, Marcinek DJ, Dorn GW, Kang YJ, Prolla TA, Santana LF, Rabinovitch PS (2011) Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res 108:837–846PubMedPubMedCentralCrossRef
42.
Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP (2000) Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest 105:1723–1730PubMedPubMedCentralCrossRef
43.
Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD (2011) Targeting fatty acid and carbohydrate oxidation—a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 1813:1333–1350PubMedCrossRef
44.
Puccio H, Simon D, Cossee M, Criqui-Filipe P, Tiziano F, Melki J, Hindelang C, Matyas R, Rustin P, Koenig M (2001) Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 27:181–186PubMedCrossRef
45.
Garnier A, Fortin D, Delomenie C, Momken I, Veksler V, Ventura-Clapier R (2003) Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol 551:491–501PubMedPubMedCentralCrossRef
46.
Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schonekess BO (1994) Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1213:263–276PubMedCrossRef
47.
Stanley WC, Lopaschuk GD, McCormack JG (1997) Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 34:25–33PubMedCrossRef
48.
Lopaschuk GD (2002) Metabolic abnormalities in the diabetic heart. Heart Fail Rev 7:149–159PubMedCrossRef
49.
Desvergne B, Michalik L, Wahli W (2006) Transcriptional regulation of metabolism. Physiol Rev 86:465–514PubMedCrossRef
50.
Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W (2006) From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45:120–159PubMedCrossRef
51.
Moller DE (2001) New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414:821–827PubMedCrossRef
52.
Lee TI, Kao YH, Chen YC, Pan NH, Chen YJ (2010) Oxidative stress and inflammation modulate peroxisome proliferator-activated receptors with regional discrepancy in diabetic heart. Eur J Clin Investig 40:692–699CrossRef
53.
Yu BC, Chang CK, Ou HY, Cheng KC, Cheng JT (2008) Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats. Cardiovasc Res 80:78–87PubMedCrossRef
54.
Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA, Okajima K, Homma S, Szabolcs MJ, Huang LS, Goldberg IJ (2007) Cardiomyocyte expression of PPARγ leads to cardiac dysfunction in mice. J Clin Invest 117(10):2791–2801PubMedPubMedCentralCrossRef
55.
Koonen DP, Glatz JF, Bonen A, Luiken JJ (2005) Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim Biophys Acta 1736:163–180PubMedCrossRef
56.
Nickerson JG, Momken I, Benton CR, Lally J, Holloway GP, Han XX, Glatz JF, Chabowski A, Luiken JJ, Bonen A (2007) Protein-mediated fatty acid uptake: regulation by contraction, AMP-activated protein kinase, and endocrine signals. Appl Physiol Nutr Metab 32:865–873PubMedCrossRef
57.
Harmon CM, Abumrad NA (1993) Binding of sulfosuccinimidyl fatty acids to adipocyte membrane proteins: isolation and amino-terminal sequence of an 88-kD protein implicated in transport of long-chain fatty acids. J Membr Biol 133:43–49PubMedCrossRef
58.
Luiken JJ, Coort SL, Koonen DP, van der Horst DJ, Bonen A, Zorzano A, Glatz JF (2004) Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters. Pflugers Arch 448:1–15PubMedCrossRef
59.
Kuang M, Febbraio M, Wagg C, Lopaschuk GD, Dyck JR (2004) Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation 109:1550–1557PubMedCrossRef
60.
Chabowski A, Coort SL, Calles-Escandon J, Tandon NN, Glatz JF, Luiken JJ, Bonen A (2005) The subcellular compartmentation of fatty acid transporters is regulated differently by insulin and by AICAR. FEBS Lett 579:2428–2432PubMedCrossRef
61.
Fukuchi K, Nozaki S, Yoshizumi T, Hasegawa S, Uehara T, Nakagawa T, Kobayashi T, Tomiyama Y, Yamashita S, Matsuzawa Y, Nishimura T (1999) Enhanced myocardial glucose use in patients with a deficiency in long-chain fatty acid transport (CD36 deficiency). J Nucl Med 40:239–243PubMed
62.
Nozaki S, Tanaka T, Yamashita S, Sohmiya K, Yoshizumi T, Okamoto F, Kitaura Y, Kotake C, Nishida H, Nakata A, Nakagawa T, Matsumoto K, Kameda-Takemura K, Tadokoro S, Kurata Y, Tomiyama Y, Kawamura K, Matsuzawa Y (1999) CD36 mediates long-chain fatty acid transport in human myocardium: complete myocardial accumulation defect of radiolabeled long-chain fatty acid analog in subjects with CD36 deficiency. Mol Cell Biochem 192:129–135PubMedCrossRef
63.
Watanabe K, Ohta Y, Toba K, Ogawa Y, Hanawa H, Hirokawa Y, Kodama M, Tanabe N, Hirono S, Ohkura Y, Nakamura Y, Kato K, Aizawa Y, Fuse I, Miyajima S, Kusano Y, Nagamoto T, Hasegawa G, Naito M (1998) Myocardial CD36 expression and fatty acid accumulation in patients with type I and II CD36 deficiency. Ann Nucl Med 12:261–266PubMedCrossRef
64.
Neely JR, Morgan HE (1974) Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol 36:413–459PubMedCrossRef
65.
Wisneski JA, Gertz EW, Neese RA, Mayr M (1987) Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. J Clin Invest 79:359–366PubMedPubMedCentralCrossRef
66.
Ellis JM, Li LO, Wu PC, Koves TR, Ilkayeva O, Stevens RD, Watkins SM, Muoio DM, Coleman RA (2010) Adipose acyl-CoA synthetase-1 directs fatty acids toward beta-oxidation and is required for cold thermogenesis. Cell Metab 12:53–64PubMedPubMedCentralCrossRef
67.
Li LO, Ellis JM, Paich HA, Wang S, Gong N, Altshuller G, Thresher RJ, Koves TR, Watkins SM, Muoio DM, Cline GW, Shulman GI, Coleman RA (2009) Liver-specific loss of long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and beta-oxidation and alters phospholipid fatty acid composition. J Biol Chem 284:27816–27826PubMedPubMedCentralCrossRef
68.
Martin MA, Gomez MA, Guillen F, Bornstein B, Campos Y, Rubio JC, de la Calzada CS, Arenas J (2000) Myocardial carnitine and carnitine palmitoyltransferase deficiencies in patients with severe heart failure. Biochim Biophys Acta 1502:330–336PubMedCrossRef
69.
He L, Kim T, Long Q, Liu J, Wang P, Zhou Y, Ding Y, Prasain J, Wood PA, Yang Q (2012) Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity. Circulation 126:1705–1716PubMedPubMedCentralCrossRef
70.
71.
Atar D, Spiess M, Mandinova A, Cierpka H, Noll G, Luscher TF (1997) Carnitine—from cellular mechanisms to potential clinical applications in heart disease. Eur J Clin Investig 27:973–976CrossRef
72.
Arsenian MA (1997) Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis 40:265–286PubMedCrossRef
73.
Regitz V, Shug AL, Fleck E (1990) Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol 65:755–760PubMedCrossRef
74.
Awan MM, Saggerson ED (1993) Malonyl-CoA metabolism in cardiac myocytes and its relevance to the control of fatty acid oxidation. Biochem J 295(Pt 1):61–66PubMedPubMedCentralCrossRef
75.
Lopaschuk GD, Witters LA, Itoi T, Barr R, Barr A (1994) Acetyl-CoA carboxylase involvement in the rapid maturation of fatty acid oxidation in the newborn rabbit heart. J Biol Chem 269:25871–25878PubMed
76.
Lopaschuk GD, Gamble J (1994) The 1993 Merck Frosst Award. Acetyl-CoA carboxylase: an important regulator of fatty acid oxidation in the heart. Can J Physiol Pharmacol 72:1101–1109PubMedCrossRef
77.
Saddik M, Gamble J, Witters LA, Lopaschuk GD (1993) Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart. J Biol Chem 268:25836–25845PubMed
78.
Dyck JR, Kudo N, Barr AJ, Davies SP, Hardie DG, Lopaschuk GD (1999) Phosphorylation control of cardiac acetyl-CoA carboxylase by cAMP-dependent protein kinase and 5′-AMP activated protein kinase. Eur J Biochem 262:184–190PubMedCrossRef
79.
Dyck JR, Lopaschuk GD (2002) Malonyl CoA control of fatty acid oxidation in the ischemic heart. J Mol Cell Cardiol 34:1099–1109PubMedCrossRef
80.
Sakamoto J, Barr RL, Kavanagh KM, Lopaschuk GD (2000) Contribution of malonyl-CoA decarboxylase to the high fatty acid oxidation rates seen in the diabetic heart. Am J Physiol Heart Circ Physiol 278:H1196–H1204PubMed
81.
Gamble J, Lopaschuk GD (1997) Insulin inhibition of 5' adenosine monophosphate-activated protein kinase in the heart results in activation of acetyl coenzyme A carboxylase and inhibition of fatty acid oxidation. Metabolism 46:1270–1274PubMedCrossRef
82.
Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD (1995) High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270:17513–17520PubMedCrossRef
83.
Spiekerkoetter U, Sun B, Zytkovicz T, Wanders R, Strauss AW, Wendel U (2003) MS/MS-based newborn and family screening detects asymptomatic patients with very-long-chain acyl-CoA dehydrogenase deficiency. J Pediatr 143:335–342PubMedCrossRef
84.
Arnold GL, Van Hove J, Freedenberg D, Strauss A, Longo N, Burton B, Garganta C, Ficicioglu C, Cederbaum S, Harding C, Boles RG, Matern D, Chakraborty P, Feigenbaum A (2009) A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 96:85–90PubMedPubMedCentralCrossRef
85.
Marci M, Ajovalasit P (2009) Medium-chain acyl-CoA dehydrogenase deficiency in an infant with dilated cardiomyopathy. Cardiol Res Pract 2009:281389PubMedPubMedCentral
86.
Hale DE, Batshaw ML, Coates PM, Frerman FE, Goodman SI, Singh I, Stanley CA (1985) Long-chain acyl coenzyme A dehydrogenase deficiency: an inherited cause of nonketotic hypoglycemia. Pediatr Res 19:666–671PubMedCrossRef
87.
Turnbull DM, Bartlett K, Stevens DL, Alberti KG, Gibson GJ, Johnson MA, McCulloch AJ, Sherratt HS (1984) Short-chain acyl-CoA dehydrogenase deficiency associated with a lipid-storage myopathy and secondary carnitine deficiency. N Engl J Med 311:1232–1236PubMedCrossRef
88.
van Grunsven EG, van Berkel E, Ijlst L, Vreken P, de Klerk JB, Adamski J, Lemonde H, Clayton PT, Cuebas DA, Wanders RJ (1998) Peroxisomal D-hydroxyacyl-CoA dehydrogenase deficiency: resolution of the enzyme defect and its molecular basis in bifunctional protein deficiency. Proc Natl Acad Sci U S A 95:2128–2133PubMedPubMedCentralCrossRef
89.
van Grunsven EG, van Berkel E, Mooijer PA, Watkins PA, Moser HW, Suzuki Y, Jiang LL, Hashimoto T, Hoefler G, Adamski J, Wanders RJ (1999) Peroxisomal bifunctional protein deficiency revisited: resolution of its true enzymatic and molecular basis. Am J Hum Genet 64:99–107PubMedPubMedCentralCrossRef
90.
91.
Tein I, De Vivo DC, Hale DE, Clarke JT, Zinman H, Laxer R, Shore A, DiMauro S (1991) Short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency in muscle: a new cause for recurrent myoglobinuria and encephalopathy. Ann Neurol 30:415–419PubMedCrossRef
92.
Kantor PF, Lucien A, Kozak R, Lopaschuk GD (2000) The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86:580–588PubMedCrossRef
93.
Saudubray JM, Mitchell G, Bonnefont JP, Schwartz G, Nuttin C, Munnich A, Brivet M, Vassault A, Demaugre F, Rabier D (1992) Approach to the patient with a fatty acid oxidation disorder. Prog Clin Biol Res 375:271–288PubMed
94.
Hale DE, Bennett MJ (1992) Fatty acid oxidation disorders: a new class of metabolic diseases. J Pediatr 121:1–11PubMedCrossRef
95.
Neely JR, Liebermeister H, Battersby EJ, Morgan HE (1967) Effect of pressure development on oxygen consumption by isolated rat heart. Am J Phys 212:804–814
96.
Williamson JR, Ford C, Illingworth J, Safer B (1976) Coordination of citric acid cycle activity with electron transport flux. Circ Res 38:I39–I51PubMed
97.
Jose AD, Stitt F (1969) Effects of hypoxia and metabolic inhibitors on the intrinsic heart rate and myocardial contractility in dogs. Circ Res 25:53–66PubMedCrossRef
98.
Patel MS, Korotchkina LG (2002) Pyruvate dehydrogenase complex as a marker of mitochondrial metabolism. Inhibition by 4-hydroxy-2-nonenal. Methods Mol Biol 186:255–263PubMed
99.
Lissens W, De Meirleir L, Seneca S, Liebaers I, Brown GK, Brown RM, Ito M, Naito E, Kuroda Y, Kerr DS, Wexler ID, Patel MS, Robinson BH, Seyda A (2000) Mutations in the X-linked pyruvate dehydrogenase (E1) alpha subunit gene (PDHA1) in patients with a pyruvate dehydrogenase complex deficiency. Hum Mutat 15:209–219PubMedCrossRef
100.
Page B, Young R, Iyer V, Suzuki G, Lis M, Korotchkina L, Patel MS, Blumenthal KM, Fallavollita JA, Canty JM Jr (2008) Persistent regional downregulation in mitochondrial enzymes and upregulation of stress proteins in swine with chronic hibernating myocardium. Circ Res 102:103–112PubMedCrossRef
101.
Sidhu S, Gangasani A, Korotchkina LG, Suzuki G, Fallavollita JA, Canty JM Jr, Patel MS (2008) Tissue-specific pyruvate dehydrogenase complex deficiency causes cardiac hypertrophy and sudden death of weaned male mice. Am J Physiol Heart Circ Physiol 295:H946–H952PubMedPubMedCentralCrossRef
102.
103.
Kalsi KK, Smolenski RT, Pritchard RD, Khaghani A, Seymour AM, Yacoub MH (1999) Energetics and function of the failing human heart with dilated or hypertrophic cardiomyopathy. Eur J Clin Investig 29:469–477CrossRef
104.
Benderdour M, Charron G, DeBlois D, Comte B, Des RC (2003) Cardiac mitochondrial NADP+-isocitrate dehydrogenase is inactivated through 4-hydroxynonenal adduct formation: an event that precedes hypertrophy development. J Biol Chem 278:45154–45159PubMedCrossRef
105.
Cooney GJ, Taegtmeyer H, Newsholme EA (1981) Tricarboxylic acid cycle flux and enzyme activities in the isolated working rat heart. Biochem J 200:701–703PubMedPubMedCentralCrossRef
106.
Moreno-Sanchez R, Torres-Marquez ME, Devars S (1990) Substrate oxidation in the myocardium. Arch Inst Cardiol Mex 60:587–591PubMed
107.
Johnson JD, Mehus JG, Tews K, Milavetz BI, Lambeth DO (1998) Genetic evidence for the expression of ATP- and GTP-specific succinyl-CoA synthetases in multicellular eucaryotes. J Biol Chem 273:27580–27586PubMedCrossRef
108.
Johnson JD, Muhonen WW, Lambeth DO (1998) Characterization of the ATP- and GTP-specific succinyl-CoA synthetases in pigeon. The enzymes incorporate the same alpha-subunit. J Biol Chem 273:27573–27579PubMedCrossRef
109.
Elpeleg O, Miller C, Hershkovitz E, Bitner-Glindzicz M, Bondi-Rubinstein G, Rahman S, Pagnamenta A, Eshhar S, Saada A (2005) Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion. Am J Hum Genet 76:1081–1086PubMedPubMedCentralCrossRef
110.
Ostergaard E, Hansen FJ, Sorensen N, Duno M, Vissing J, Larsen PL, Faeroe O, Thorgrimsson S, Wibrand F, Christensen E, Schwartz M (2007) Mitochondrial encephalomyopathy with elevated methylmalonic acid is caused by SUCLA2 mutations. Brain 130:853–861PubMedCrossRef
111.
Carrozzo R, Dionisi-Vici C, Steuerwald U, Lucioli S, Deodato F, Di Giandomenico S, Bertini E, Franke B, Kluijtmans LA, Meschini MC, Rizzo C, Piemonte F, Rodenburg R, Santer R, Santorelli FM, van Rooij A, Vermunt-de Koning D, Morava E, Wevers RA (2007) SUCLA2 mutations are associated with mild methylmalonic aciduria, Leigh-like encephalomyopathy, dystonia and deafness. Brain 130:862–874PubMedCrossRef
112.
Morava E, Steuerwald U, Carrozzo R, Kluijtmans LA, Joensen F, Santer R, Dionisi-Vici C, Wevers RA (2009) Dystonia and deafness due to SUCLA2 defect; clinical course and biochemical markers in 16 children. Mitochondrion 9:438–442PubMedCrossRef
113.
Dupourque D, Kun E (1969) Malate dehydrogenases of ox kidney. 2. Two substrate kinetic and inhibition analyses. Eur J Biochem 7:247–252PubMedCrossRef
114.
Sharov VG, Goussev A, Lesch M, Goldstein S, Sabbah HN (1998) Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 30:1757–1762PubMedCrossRef
115.
Green DE, Tzagoloff A (1966) The mitochondrial electron transfer chain. Arch Biochem Biophys 116:293–304PubMedCrossRef
116.
Casademont J, Miro O (2002) Electron transport chain defects in heart failure. Heart Fail Rev 7:131–139PubMedCrossRef
117.
Smeitink JA, Loeffen JL, Triepels RH, Smeets RJ, Trijbels JM, van den Heuvel LP (1998) Nuclear genes of human complex I of the mitochondrial electron transport chain: state of the art. Hum Mol Genet 7:1573–1579PubMedCrossRef
118.
Robinson BH (1998) Human complex I deficiency: clinical spectrum and involvement of oxygen free radicals in the pathogenicity of the defect. Biochim Biophys Acta 1364:271–286PubMedCrossRef
119.
Karamanlidis G, Lee CF, Garcia-Menendez L, Kolwicz SC Jr, Suthammarak W, Gong G, Sedensky MM, Morgan PG, Wang W, Tian R (2013) Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metab 18:239–250PubMedPubMedCentralCrossRef
120.
Hoekstra AS, Bayley JP (2013) The role of complex II in disease. Biochim Biophys Acta 1827:543–551PubMedCrossRef
121.
Benit P, Lebon S, Rustin P (2009) Respiratory-chain diseases related to complex III deficiency. Biochim Biophys Acta 1793:181–185PubMedCrossRef
122.
123.
Maack C, Dabew ER, Hohl M, Schafers HJ, Bohm M (2009) Endogenous activation of mitochondrial KATP channels protects human failing myocardium from hydroxyl radical-induced stunning. Circ Res 105:811–817PubMedCrossRef
124.
125.
Li JM, Shah AM (2004) Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol 287:R1014–R1030PubMedCrossRef
126.
Sinatra ST (2009) Metabolic cardiology: an integrative strategy in the treatment of congestive heart failure. Altern Ther Health Med 15:44–52PubMed
127.
Gupta A, Akki A, Wang Y, Leppo MK, Chacko VP, Foster DB, Caceres V, Shi S, Kirk JA, Su J, Lai S, Paolocci N, Steenbergen C, Gerstenblith G, Weiss RG (2012) Creatine kinase-mediated improvement of function in failing mouse hearts provides causal evidence the failing heart is energy starved. J Clin Invest 122:291–302PubMedCrossRef
128.
Middleton E Jr (1998) Effect of plant flavonoids on immune and inflammatory cell function. Adv Exp Med Biol 439:175–182PubMedCrossRef
129.
Solanki I, Parihar P, Mansuri ML, Parihar MS (2015) Flavonoid-based therapies in the early management of neurodegenerative diseases. Adv Nutr 6:64–72PubMedPubMedCentralCrossRef
130.
de Groot H, Rauen U (1998) Tissue injury by reactive oxygen species and the protective effects of flavonoids. Fundam Clin Pharmacol 12:249–255PubMedCrossRef
131.
Hertog MG, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F, Giampaoli S, Jansen A, Menotti A, Nedeljkovic S (1995) Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med 155:381–386PubMedCrossRef
132.
Mueller M, Lukas B, Novak J, Simoncini T, Genazzani AR, Jungbauer A (2008) Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists. J Agric Food Chem 56:11621–11630PubMedCrossRef
133.
Mueller M, Jungbauer A (2009) Peroxisome proliferator-activated receptor gamma is constitutively activated in yeast. Anal Biochem 385:365–367PubMedCrossRef
134.
Jungbauer A, Medjakovic S (2012) Anti-inflammatory properties of culinary herbs and spices that ameliorate the effects of metabolic syndrome. Maturitas 71:227–239PubMedCrossRef
135.
Shin DW, Kim SN, Lee SM, Lee W, Song MJ, Park SM, Lee TR, Baik JH, Kim HK, Hong JH, Noh M (2009) (−)-Catechin promotes adipocyte differentiation in human bone marrow mesenchymal stem cells through PPAR gamma transactivation. Biochem Pharmacol 77:125–133PubMedCrossRef
136.
Kim B, Choi YE, Kim HS (2014) Eruca sativa and its flavonoid components, quercetin and isorhamnetin, improve skin barrier function by activation of peroxisome proliferator-activated receptor (PPAR)-alpha and suppression of inflammatory cytokines. Phytother Res 28:1359–1366PubMedCrossRef
137.
van Bilsen M, van Nieuwenhoven FA (2010) PPARs as therapeutic targets in cardiovascular disease. Expert Opin Ther Targets 14:1029–1045PubMedCrossRef
138.
Hennuyer N, Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fievet C (2005) PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 25:1897–1902PubMedCrossRef
139.
Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, Burton CA, Tedgui A, Fruchart JC, Fievet C, Wright SD, Staels B (2002) Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 277:48051–48057PubMedCrossRef
140.
Whitman SC, Kurowska EM, Manthey JA, Daugherty A (2005) Nobiletin, a citrus flavonoid isolated from tangerines, selectively inhibits class A scavenger receptor-mediated metabolism of acetylated LDL by mouse macrophages. Atherosclerosis 178:25–32PubMedCrossRef
141.
Wei T, Xiong FF, Wang SD, Wang K, Zhang YY, Zhang QH (2014) Flavonoid ingredients of Ginkgo biloba leaf extract regulate lipid metabolism through Sp1-mediated carnitine palmitoyltranferase 1A up-regulation. J Biomed Sci 21:87PubMedPubMedCentralCrossRef
142.
Baiges I, Palmfeldt J, Blade C, Gregersen N, Arola L (2010) Lipogenesis is decreased by grape seed proanthocyanidins according to liver proteomics of rats fed a high fat diet. Mol Cell Proteomics 9:1499–1513PubMedPubMedCentralCrossRef
143.
Kamisoyama H, Honda K, Tominaga Y, Yokota S, Hasegawa S (2008) Investigation of the anti-obesity action of licorice flavonoid oil in diet-induced obese rats. Biosci Biotechnol Biochem 72:3225–3231PubMedCrossRef
144.
Watanabe N, Inagawa K, Shibata M, Osakabe N (2014) Flavan-3-ol fraction from cocoa powder promotes mitochondrial biogenesis in skeletal muscle in mice. Lipids Health Dis 13:64PubMedPubMedCentralCrossRef
145.
Aoki F, Honda S, Kishida H, Kitano M, Arai N, Tanaka H, Yokota S, Nakagawa K, Asakura T, Nakai Y, Mae T (2007) Suppression by licorice flavonoids of abdominal fat accumulation and body weight gain in high-fat diet-induced obese C57BL/6J mice. Biosci Biotechnol Biochem 71:206–214PubMedCrossRef
146.
Bronnikov GE, Kulagina TP, Aripovsky AV (2009) Dietary supplementation of old mice with flavonoid dihydroquercetin causes recovery of the mitochondrial enzyme activities in skeletal muscles. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology 3:453–458CrossRef
147.
Govindasamy C, Al-Numair KS, Veeramani C, Alsaif MA, Almajwal M (2015) Protective effect of kaempferol, a flavonoid compound, on oxidative mitochondrial damage in streptozotocin-induced diabetic rats. Progress in Nutrition, 17
148.
Alam MA, Subhan N, Rahman MM, Uddin SJ, Reza HM, Sarker SD (2014) Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. Adv Nutr 5:404–417PubMedPubMedCentralCrossRef
149.
Jayachandran KS, Vasanthi HR, Rajamanickama GV (2010) Flavonoid rich fraction of Dioscorea bulbifera Linn. (Yam) enhances mitochondrial enzymes and antioxidant status and thereby protects heart from isoproterenol induced myocardial infarction. Curr Pharm Biotechnol 11:887–894PubMedCrossRef
150.
Sandhir R, Mehrotra A (2013) Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid: implications in Huntington's disease. Biochim Biophys Acta 1832:421–430PubMedCrossRef
151.
Moini H, Arroyo A, Vaya J, Packer L (1999) Bioflavonoid effects on the mitochondrial respiratory electron transport chain and cytochrome c redox state. Redox Rep 4:35–41PubMedCrossRef
152.
Barnes S, Peterson TG (1995) Biochemical targets of the isoflavone genistein in tumor cell lines. Proc Soc Exp Biol Med 208:103–108PubMedCrossRef
153.
Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218–220PubMedCrossRef
154.
Yang CS, Kim S, Yang GY, Lee MJ, Liao J, Chung JY, Ho CT (1999) Inhibition of carcinogenesis by tea: bioavailability of tea polyphenols and mechanisms of actions. Proc Soc Exp Biol Med 220:213–217PubMedCrossRef
155.
Libby P (2006) Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 83:456S–460SPubMed
156.
157.
158.
159.
Weisfeldt ML, Zieman SJ (2007) Advances in the prevention and treatment of cardiovascular disease. Health Aff (Millwood ) 26:25–37CrossRef
160.
161.
162.
Arai Y, Watanabe S, Kimira M, Shimoi K, Mochizuki R, Kinae N (2000) Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr 130:2243–2250PubMed
Metadaten
Titel
Metabolic enzymes dysregulation in heart failure: the prospective therapy
verfasst von
Priyanka Parihar
Mordhwaj Singh Parihar
Publikationsdatum
17.11.2016
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 1/2017
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-016-9588-x

Weitere Artikel der Ausgabe 1/2017

Heart Failure Reviews 1/2017 Zur Ausgabe

OriginalPaper

Atrial fibrillation and cognitive function in patients with heart failure: a systematic review and meta-analysis

OriginalPaper

Left atrium: the last bulwark before overt heart failure

ReviewPaper

Adherence to recommended exercise guidelines in patients with heart failure

OriginalPaper

Molecular mechanisms of heart failure: insights from Drosophila

OriginalPaper

Genomic and rapid effects of aldosterone: what we know and do not know thus far

ReviewPaper

Obesity paradox in heart failure: statistical artifact, or impetus to rethink clinical practice?

Neu im Fachgebiet Kardiologie

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation
weitere anzeigen

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen